The inhaler corticosteroid device market size has grown strongly in recent years. It will grow from $16.83 billion in 2025 to $17.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of asthma and copd, rising awareness about inhaler therapies, government initiatives for respiratory health, advancements in metered-dose inhalers, growth of hospital and homecare facilities.
The inhaler corticosteroid device market size is expected to see strong growth in the next few years. It will grow to $23.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to integration of ai and iot in inhaler devices, development of eco-friendly inhalers, expansion of telehealth services, personalized medication delivery, rising demand in emerging markets. Major trends in the forecast period include smart inhaler integration, personalized dosage management, telehealth-enabled monitoring, eco-friendly & sustainable device design, advanced aerosol delivery technologies.
The rising prevalence of respiratory diseases is expected to drive the growth of the inhaler corticosteroid device market in the coming years. Respiratory diseases encompass a variety of conditions affecting the lungs and airways, which impair proper and efficient breathing. The increase in respiratory diseases is attributed to growing air pollution, exposing people to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices treat respiratory diseases by delivering anti-inflammatory medication directly to the lungs, helping to reduce inflammation and improve breathing. For example, in June 2025, the UK’s Office for Health Improvement and Disparities reported that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population - a 7% increase compared to the previous year. Therefore, the growing prevalence of respiratory diseases is fueling the expansion of the inhaler corticosteroid device market.
Leading companies in the inhaler corticosteroid device market are focusing on launching innovative solutions, such as rescue inhalers that combine albuterol and budesonide to improve treatment efficacy and provide patients with a more convenient, dual-action therapy within a single device. An inhaler combining albuterol and budesonide is a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to reduce inflammation, offering quick symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical company, introduced AIRSUPRA, the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is intended for as-needed use to relieve acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma attacks. It represents a novel approach by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with approval based on clinical trials demonstrating its superiority over albuterol alone in preventing asthma exacerbations.
In May 2023, Phillips-Medisize Corporation, a U.S.-based medical technology and drug-delivery solutions provider and a subsidiary of Molex LLC, completed the acquisition of Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Phillips-Medisize Corporation intends to broaden its inhaled drug-delivery portfolio, enhance its end-to-end capabilities in inhalation device design and development, and accelerate innovation in combination products for pharmaceutical and biotech clients. Vectura Group Ltd. is a UK-based pharmaceutical firm that specializes in inhalation formulations, device development, and dry-powder inhaler technologies.
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH.
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaler corticosteroid device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the inhaler corticosteroid device market by increasing the cost of imported components such as precision valves, propellants, and electronics used in smart inhalers. These tariffs particularly affect segments like metered-dose inhalers and battery-operated soft mist inhalers, with regions such as Asia-Pacific and North America experiencing higher production costs. While tariffs may slow market expansion due to increased prices, they also encourage local manufacturing and innovation, promoting the development of cost-efficient devices and regional supply chain diversification.
The inhaler corticosteroid device market research report is one of a series of new reports that provides inhaler corticosteroid device market statistics, including inhaler corticosteroid device industry global market size, regional shares, competitors with a inhaler corticosteroid device market share, detailed inhaler corticosteroid device market segments, market trends and opportunities, and any further data you may need to thrive in the inhaler corticosteroid device industry. This inhaler corticosteroid device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An inhaler corticosteroid device is a specialized medical instrument designed to deliver anti-inflammatory corticosteroid medication directly into the lungs. This targeted delivery reduces swelling and irritation in the airways caused by chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By acting locally in the lungs, these devices help control and prevent symptoms like wheezing, shortness of breath, and coughing, while limiting the systemic side effects often associated with oral corticosteroids.
The primary types of inhaler corticosteroid devices include metered-dose inhalers, dry powder inhalers, and soft mist inhalers. Metered-dose inhalers (MDIs) are portable devices that release a precise, measured dose of medication into the lungs as an aerosol. These inhalers use various drug formulations such as fluticasone propionate, budesonide, beclomethasone, and mometasone furoate. They are distributed through online and retail pharmacies, direct sales, and hospital pharmacies. These devices are widely used for managing conditions like asthma and COPD, with end users including hospitals, home care providers, specialty clinics, and others.
The inhaler corticosteroid device market consists of sales of nebulizer solutions, manual soft mist inhalers, conventional metered-dose inhalers, and combination inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The inhaler corticosteroid device market size is expected to see strong growth in the next few years. It will grow to $23.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to integration of ai and iot in inhaler devices, development of eco-friendly inhalers, expansion of telehealth services, personalized medication delivery, rising demand in emerging markets. Major trends in the forecast period include smart inhaler integration, personalized dosage management, telehealth-enabled monitoring, eco-friendly & sustainable device design, advanced aerosol delivery technologies.
The rising prevalence of respiratory diseases is expected to drive the growth of the inhaler corticosteroid device market in the coming years. Respiratory diseases encompass a variety of conditions affecting the lungs and airways, which impair proper and efficient breathing. The increase in respiratory diseases is attributed to growing air pollution, exposing people to harmful particles that damage lung tissue and trigger chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices treat respiratory diseases by delivering anti-inflammatory medication directly to the lungs, helping to reduce inflammation and improve breathing. For example, in June 2025, the UK’s Office for Health Improvement and Disparities reported that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population - a 7% increase compared to the previous year. Therefore, the growing prevalence of respiratory diseases is fueling the expansion of the inhaler corticosteroid device market.
Leading companies in the inhaler corticosteroid device market are focusing on launching innovative solutions, such as rescue inhalers that combine albuterol and budesonide to improve treatment efficacy and provide patients with a more convenient, dual-action therapy within a single device. An inhaler combining albuterol and budesonide is a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to reduce inflammation, offering quick symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical company, introduced AIRSUPRA, the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is intended for as-needed use to relieve acute bronchoconstriction symptoms and reduce airway inflammation, thereby lowering the risk of severe asthma attacks. It represents a novel approach by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with approval based on clinical trials demonstrating its superiority over albuterol alone in preventing asthma exacerbations.
In May 2023, Phillips-Medisize Corporation, a U.S.-based medical technology and drug-delivery solutions provider and a subsidiary of Molex LLC, completed the acquisition of Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Phillips-Medisize Corporation intends to broaden its inhaled drug-delivery portfolio, enhance its end-to-end capabilities in inhalation device design and development, and accelerate innovation in combination products for pharmaceutical and biotech clients. Vectura Group Ltd. is a UK-based pharmaceutical firm that specializes in inhalation formulations, device development, and dry-powder inhaler technologies.
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH.
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaler corticosteroid device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the inhaler corticosteroid device market by increasing the cost of imported components such as precision valves, propellants, and electronics used in smart inhalers. These tariffs particularly affect segments like metered-dose inhalers and battery-operated soft mist inhalers, with regions such as Asia-Pacific and North America experiencing higher production costs. While tariffs may slow market expansion due to increased prices, they also encourage local manufacturing and innovation, promoting the development of cost-efficient devices and regional supply chain diversification.
The inhaler corticosteroid device market research report is one of a series of new reports that provides inhaler corticosteroid device market statistics, including inhaler corticosteroid device industry global market size, regional shares, competitors with a inhaler corticosteroid device market share, detailed inhaler corticosteroid device market segments, market trends and opportunities, and any further data you may need to thrive in the inhaler corticosteroid device industry. This inhaler corticosteroid device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An inhaler corticosteroid device is a specialized medical instrument designed to deliver anti-inflammatory corticosteroid medication directly into the lungs. This targeted delivery reduces swelling and irritation in the airways caused by chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By acting locally in the lungs, these devices help control and prevent symptoms like wheezing, shortness of breath, and coughing, while limiting the systemic side effects often associated with oral corticosteroids.
The primary types of inhaler corticosteroid devices include metered-dose inhalers, dry powder inhalers, and soft mist inhalers. Metered-dose inhalers (MDIs) are portable devices that release a precise, measured dose of medication into the lungs as an aerosol. These inhalers use various drug formulations such as fluticasone propionate, budesonide, beclomethasone, and mometasone furoate. They are distributed through online and retail pharmacies, direct sales, and hospital pharmacies. These devices are widely used for managing conditions like asthma and COPD, with end users including hospitals, home care providers, specialty clinics, and others.
The inhaler corticosteroid device market consists of sales of nebulizer solutions, manual soft mist inhalers, conventional metered-dose inhalers, and combination inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Inhaler Corticosteroid Device Market Characteristics
3. Inhaler Corticosteroid Device Market Supply Chain Analysis
4. Global Inhaler Corticosteroid Device Market Trends and Strategies
5. Inhaler Corticosteroid Device Market Analysis of End Use Industries
7. Global Inhaler Corticosteroid Device Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Inhaler Corticosteroid Device Total Addressable Market (TAM) Analysis for the Market
9. Inhaler Corticosteroid Device Market Segmentation
10. Inhaler Corticosteroid Device Market Regional and Country Analysis
11. Asia-Pacific Inhaler Corticosteroid Device Market
12. China Inhaler Corticosteroid Device Market
13. India Inhaler Corticosteroid Device Market
14. Japan Inhaler Corticosteroid Device Market
15. Australia Inhaler Corticosteroid Device Market
16. Indonesia Inhaler Corticosteroid Device Market
17. South Korea Inhaler Corticosteroid Device Market
18. Taiwan Inhaler Corticosteroid Device Market
19. South East Asia Inhaler Corticosteroid Device Market
20. Western Europe Inhaler Corticosteroid Device Market
21. UK Inhaler Corticosteroid Device Market
22. Germany Inhaler Corticosteroid Device Market
23. France Inhaler Corticosteroid Device Market
24. Italy Inhaler Corticosteroid Device Market
25. Spain Inhaler Corticosteroid Device Market
26. Eastern Europe Inhaler Corticosteroid Device Market
27. Russia Inhaler Corticosteroid Device Market
28. North America Inhaler Corticosteroid Device Market
29. USA Inhaler Corticosteroid Device Market
30. Canada Inhaler Corticosteroid Device Market
31. South America Inhaler Corticosteroid Device Market
32. Brazil Inhaler Corticosteroid Device Market
33. Middle East Inhaler Corticosteroid Device Market
34. Africa Inhaler Corticosteroid Device Market
36. Inhaler Corticosteroid Device Market Competitive Landscape and Company Profiles
37. Inhaler Corticosteroid Device Market Other Major and Innovative Companies
40. Inhaler Corticosteroid Device Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Inhaler Corticosteroid Device Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses inhaler corticosteroid device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for inhaler corticosteroid device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inhaler corticosteroid device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Metered-Dose Inhalers; Dry Powder Inhalers; Soft Mist Inhalers2) By Formulation Type: Fluticasone Propionate; Budesonide; Beclomethasone; Mometasone Furoate
3) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Direct Sales; Hospital Pharmacies
4) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Other Applications
5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers; Breath-Actuated Metered-Dose Inhalers; Spacer-Integrated Metered-Dose Inhalers2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers; Multi-Dose Dry Powder Inhalers; Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers; Battery-Operated Soft Mist Inhalers
Companies Mentioned: AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Teijin Pharma Limited; Sun Pharmaceutical Industries Limited; Aurobindo Pharma Limited; Chiesi Farmaceutici S.p.A.; Cipla Limited; Hikma Pharmaceuticals PLC; Amneal Pharmaceuticals Inc.; Mundipharma International Limited; Lupin Limited; Zydus Lifesciences Limited; Recipharm AB; Glenmark Pharmaceuticals Limited; Orion Corporation; Beximco Pharmaceuticals Limited; PARI Medical Holding GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Inhaler Corticosteroid Device market report include:- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Teijin Pharma Limited
- Sun Pharmaceutical Industries Limited
- Aurobindo Pharma Limited
- Chiesi Farmaceutici S.p.A.
- Cipla Limited
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals Inc.
- Mundipharma International Limited
- Lupin Limited
- Zydus Lifesciences Limited
- Recipharm AB
- Glenmark Pharmaceuticals Limited
- Orion Corporation
- Beximco Pharmaceuticals Limited
- PARI Medical Holding GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.98 Billion |
| Forecasted Market Value ( USD | $ 23.18 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
